the vaccine

[키워드] 1:1 95% CI adenoviral vector vaccine Ageusia analysed Anosmia assigned AstraZeneca AZD1222 B.1.1.7 B.1.1.7 lineage B.1.1.7 variant booster dose booster doses calculated canonical ChAdOx1 ChAdOx1 nCoV-19 Clinical research Clinical vaccine efficacy Coalition collected cough COVID-19 COVID-19 disease disease dominant Efficacy efficacy analysis efficacy cohort enrolled Exploratory analysis female Fever finding funding Genomics geometric mean geometric mean ratio groups in vitro Infection Innovation ISRCTN Lineage lineages MenACWY microneutralisation assay NAAT NAAT positive NAAT positive swab network neutralisation activity neutralising antibody response Neutralising antibody responses NIHR NIHR Oxford Biomedical Research Centre non-B.1.1.7 variant nose and throat nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant phase 2/3 Poisson regression model positive sample post-hoc analysis provided randomised controlled trial Randomly receive recruited reduced Registered Relative risk risk robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant second dose second dose of vaccine sequenced seronegative participant seronegative participants Shortness of breath South Swab swabs symptomatic symptomatic COVID-19 symptoms of COVID-19 tested the vaccine throat swabs Trial upper airway upper airway swab Vaccine vaccine efficacy vaccine-induced antibodies vaccine-induced antibody Valley variant variant of SARS-CoV-2 Victoria Victoria lineage virus neutralisation activity were measured
[DOI] 10.1016/S0140-6736(21)00628-0 PMC 바로가기 [Article Type] Clinical Trial